Health & Environmental Research Online (HERO)


Print Feedback Export to File
2750774 
Journal Article 
Ex vivo evaluation of pidotimod activity in patients with chronic obstructive pulmonary disease 
Benetti, GP; Illeni, MT; Passera, A; Bombelli, G; Uslenghi, C; Et al 
1994 
1 
Arzneimittel-Forschung
ISSN: 0004-4172
EISSN: 1616-7066 
IPA/96/1091098 
Forsch 
REF 14 
IPA COPYRIGHT: ASHP A randomized, double-blind, parallel study was conducted to evaluate the activity of pidotimod in 52 patients, ages 29-82 yr, with chronic obstructive pulmonary disease (COPD) who received oral pidotimod 800 mg twice daily for 30 days. Results showed that in patients with COPD, pidotimod potentiates T-cell activity. The effects on T cells appeared after 15 days of treatment and lasted for 5 wk after the end of therapy. The drug was well tolerated. It was concluded that pidotimod can potentiate the immune response in patients affected with COPD because of stimulation of the T-cell compartment.